<DOC>
	<DOCNO>NCT01791660</DOCNO>
	<brief_summary>Protocol intend clinical evaluation fat reduction male breast ( pseudogynecomastia ) use ZELTIQ Coolsculpting System . The ZELTIQ Coolsculpting system receive market clearance U.S.FDA non-invasive fat layer reduction flank , commercially available . Primary study endpoint change shape reduction fat breast establish photographic image ultrasound imaging treat area . Secondary endpoint provide supportive data evaluate device performance ( subject satisfaction &amp; fat reduction measure ultrasound ) .</brief_summary>
	<brief_title>Targeted Fat Reduction Pseudogynecomastia Male Breast Using ZELTIQ Coolsculpting System</brief_title>
	<detailed_description>desire</detailed_description>
	<mesh_term>Gynecomastia</mesh_term>
	<criteria>INCLUDED : 1 . Male subject &gt; 18 year age &lt; 70 year age . 2 . Subject clearly visible , palpable , excess fatty tissue breast area , minimal fibrous tissue . 3 . Subject weight change exceed 10 pound precede month . 4 . Subject agree maintain weight ( i.e. , within +/ 5 pound ) make major change diet lifestyle course study . 5 . Subject read sign write informed consent form . EXCLUDED : 1 . Subject surgical procedure ( ) area intend treatment . 2 . Subject invasive fat reduction procedure ( e.g. , liposuction mesotherapy ) area intend treatment . 3 . Subject noninvasive fat reduction and/or body contour procedure area intend treatment . 4 . Subject need administer , know history , subcutaneous injection area intend treatment ( e.g. , heparin , insulin ) within past month . 5 . Subject known history cryoglobulinemia , cold urticaria , paroxysmal cold hemoglobinuria . 6 . Subject known history Raynaud 's disease , know condition response cold exposure limit blood flow skin . 7 . Subject history bleed disorder take medication investigator 's opinion may increase subject 's risk bruising . 8 . Subject body mass index ( BMI ) exceed 30 . BMI define weight pound multiply 703 divide square height inch . 9 . Subject take take diet pill diet supplement within past month . 10 . Subject dermatological condition , moderate excessive skin laxity , scar location treatment site may interfere treatment evaluation . 11 . Subject unable unwilling comply study requirement . 12 . Subject currently enrol clinical study unapproved investigational drug device . 13 . Personal history previous breast malignancy . 14 . Any condition laboratory value would , professional opinion investigator , potentially affect subject 's response integrity data would pose unacceptable risk subject . 15 . Subject take medication could cause abnormal breast enlargement include limited : digoxin , furosemide , gonadotropin , clomiphene , phenytoin , exogenous testosterone , ketoconazole , metronidazole , alkylating agent , cisplatin , spironolactone , cimetidine , flutamide , finasteride , etomidate , isonicotinic acid hydrazide , methyldopa , busulfan , tricyclic antidepressant , diazepam , penicillamine , omeprazole , phenothiazine , calcium channel blocker , angiotensinconverting enzyme ( ACE ) inhibitor . 16 . Recent history ( within past 5 year ) substance abuse ( alcohol , marijuana heroin ) . 17 . Subject history follow medical condition : Klinefelter syndrome , Congenital anorchia , Testicular trauma , Testicular torsion , Viral orchitis , Kallmann syndrome , Pituitary tumor , Malignancies increase serum level hCG ( eg , large cell lung cancer , gastric carcinoma , renal cell carcinoma , hepatoma ) , Renal failure , Hyperthyroidism , Malnutrition , Androgen insensitivity syndrome , Fivealphareductase deficiency syndrome</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>